KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $23.0 million.

  • Bionano Genomics' Total Current Liabilities fell 3026.71% to $23.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.0 million, marking a year-over-year decrease of 3026.71%. This contributed to the annual value of $37.3 million for FY2024, which is 6266.65% down from last year.
  • According to the latest figures from Q3 2025, Bionano Genomics' Total Current Liabilities is $23.0 million, which was down 3026.71% from $24.2 million recorded in Q2 2025.
  • Bionano Genomics' 5-year Total Current Liabilities high stood at $100.0 million for Q4 2023, and its period low was $7.2 million during Q1 2021.
  • For the 5-year period, Bionano Genomics' Total Current Liabilities averaged around $32.9 million, with its median value being $32.9 million (2024).
  • Per our database at Business Quant, Bionano Genomics' Total Current Liabilities crashed by 6908.31% in 2021 and then skyrocketed by 17875.38% in 2023.
  • Over the past 5 years, Bionano Genomics' Total Current Liabilities (Quarter) stood at $21.8 million in 2021, then soared by 64.3% to $35.9 million in 2022, then surged by 178.75% to $100.0 million in 2023, then plummeted by 62.67% to $37.3 million in 2024, then crashed by 38.47% to $23.0 million in 2025.
  • Its last three reported values are $23.0 million in Q3 2025, $24.2 million for Q2 2025, and $26.4 million during Q1 2025.